Related Experiment Videos
Hormone replacement therapy and plasma homocysteine levels
W M van Baal1, R G Smolders, M J van der Mooren
1Institute for Cardiovascular Research, Vrije Universiteit, the Department of Obstetrics and Gynecology, Amsterdam, The Netherlands.
Obstetrics and Gynecology
|October 8, 1999
Summary
Combined hormone replacement therapy significantly reduced homocysteine levels in postmenopausal women. Those with higher baseline homocysteine benefited most from this therapy.
Area of Science:
- Endocrinology
- Cardiovascular Health
- Metabolic Health
Background:
- Elevated homocysteine is a risk factor for cardiovascular disease.
- Hormone replacement therapy (HRT) is used to manage menopausal symptoms.
- The impact of HRT on homocysteine metabolism requires further investigation.
Purpose of the Study:
- To compare the effects of combined estradiol-progestogen therapy versus unopposed estradiol on homocysteine levels.
- To assess the influence of treatment duration (4 vs. 12 weeks) on homocysteine concentrations.
- To identify patient subgroups that may benefit most from HRT regarding homocysteine reduction.
Main Methods:
- Prospective, 12-week study involving 59 healthy postmenopausal women.
- Random assignment to groups: combined estradiol-progestogen, estradiol-only, or placebo.
- Fasting plasma total homocysteine concentrations were measured at baseline and study completion.
Main Results:
- Combined estradiol-progestogen therapy led to a significant 9.4% reduction in homocysteine.
- Estradiol-only therapy showed a 5.1% reduction, while placebo increased levels by 2.4%.
- Reductions were observed as early as 4 weeks, with greater benefits in women with higher baseline homocysteine.
Conclusions:
- Combined estradiol-progestogen HRT effectively reduces fasting total homocysteine concentrations.
- Postmenopausal women with elevated homocysteine levels experience the greatest benefit.
- The progestogens used did not negatively impact homocysteine metabolism.